Location

Rochester, Minnesota

Contact

galanis.evanthia@mayo.edu

Summary

Long-Term Research Aim:

To successfully treat solid tumors employing gene transfer and virotherapy approaches.

Mid-Term Research Aims:

  1. To test oncolytic measles virus derivatives in preclinical tumor models with special focus on gliomas, breast cancer and prostate cancer.
  2. To retarget measle virus strains against tumor-specific antigens.
  3. To test novel viral delivery approaches such as cell mediated delivery in preclinical models.
  4. To test immunomodulatory strategies as a means of further increasing viral replication in vivo.
  5. To continue with the current and new phase I/phase II gene therapy and virotherapy clinical trials in solid tumors in order to translate promising transgene/vector systems and oncolytic viruses to the clinic.

Clinical Trials:

I am principal investigator in several clinical trials through the Division of Medical Oncology, examining the therapeutic potential of: 1) a measles virus derivative encoding the human carcinoembryonic antigen (MV-CEA) in patients with recurrent glioblastoma multiforme; 2) a measles virus derivative encoding the sodium iodine symporter gene (MV-NIS) in patients with recurrent ovarian cancer; 3) a phase II trial of Reovirus in patients with metastatic melanoma; 4) a phase II trial of vaccinia virus in patients with hepatocellular carcinoma; 5) several trials of small molecule cell cycle inhibitors such as histone deacetylase inhibitors, proteasome inhibitors, sarc-kinase inhibitors and antiangiogenesis approaches in glioma patients, conducted through the North Central Cancer Treatment Group (NCCTG).

Recent Publications

See my publications

Professional Details

Primary Appointment

  1. Oncology

Academic Rank

  1. Professor of Oncology

Education

  1. Fellow - Hematology/Oncology Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
  2. Resident - Internal Medicine Mayo Graduate School of Medicine, Mayo Clinic College of Medicine
  3. D.Sc - ""Development and application of quantitative immunoenzymatic assays (ELISAS) and immunoblotting techniques in the study of specificity and title of M1- antimitochondrial antibodies (M2-AMA). Athens University School of Medicine, Athens
  4. MD Athens University School of Medicine, Athens
.
BIO-00083446

Mayo Clinic Footer